Kocayigit I,Yaylaci S,Osken A,Aydın E,Sahinkus S,Can Y .2019 .Comparison of effects of thrombolytic therapy and primary percutaneous coronary intervention in elderly patients with acute ST-segment elevation myocardial infarction on inhospital, six-month, and one-year mortality. Arch Med Sci Atheroscler Dis, 4 : e82-8.
.2012 .Association of bleeding and in-hospital mortality in black and white patients with ST-segment elevation myocardial infarction receiving reperfusion. Circulation, 125(14) : 1727-34.
.2010 .Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med, 362(23) : 2155-65.
Terkelsen CJ,Sørensen JT,Maeng M,Jensen LO,Tilsted HH,Vach W .2010 .System de-lay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA, 304(7) : 763-71.
Armstrong PW,Boden WE .2011 .Reperfusion paradox in STsegment elevation myocardial infarction. Ann Intern Med, 155(6) : 389-91.
Yudi MB,Sharma SK,Tang GHL,Kini A .2018 .Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement. J Am Coll Cardiol, 71(12) : 1360-78.
.2008 .Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation, 117(24) : 3152-6.
Galasso G,Schiekofer S,D'Anna C,Gioia GD,Piccolo R,Niglio T .2014 .No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology, 65(3) : 180-9.
Reffelmann T,Kloner RA. Kloner .2002 .The “no-reflow” phenomenon: basic science and clinical correlates. Heart, 87(2) : 162-8.
Kelly RV,Cohen MG,Runge MS,Stouffer GA .2004 .The no-reflow phenomenon in coronary arteries. J Thromb Haemost, 2(11) : 1903-7.
Ito H .2006 .No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med, 3(9) : 499-506.
Jaffe R,Charron T,Puley G,Dick A,Strauss BH .2008 .Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation, 117(24) : 3152-6.
Wang L,Cheng Z,Gu Y,Peng D Y .2015 .Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int, : 382086.
Arab TA,Rafik R,Etriby AL .2016 .Efficacy and safety of local intracoronary drug delivery in treatment of no-reflow phenomenon: a pilot study. J Interven Cardiol, 29(5) : 496-504.
Rao PS. Bhardwaj R,Nath RK .2023 .No reflow phenomenon in CAD patients after percutaneous coronary intervention: A prospective hospital based observational study. Indian Heart J, 75(2) : 156-9.
Yang L,Cong H,Lu Y,Chen X,Liu Y. .2020 .Prediction of noreflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore), 99(26) : e20152.
Shahri BM .2020 .Vojdanparast, Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents. Razavi Int J Med, 8(1234) : 1-7.
Akpek M,Sahin O,Sarli B,Baktir AO,Saglam H,Urkmez S .2015 .Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology, 66(6) : 560-7.
Aksu T,Guler TE,Colak A,Baysal E,Durukan M,Sen T .2015 .Intracoronary epinephrine in the treatment of refractory noreflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord, 15 : 10.